The present invention relates to closing openings in a vessel or other body cavity. More specifically, the present invention relates to an expandable closure device having a barrier coating layer to delay expansion of the device when placed into the body cavity.
There are a wide variety of procedures which require gaining internal access to blood vessels or other body cavities. Many such procedures also require the insertion of treatment devices into the blood vessel or body cavity. Many of these procedures utilize accessible arteries as entry points for the treatment devices. For example, some such arteries include the femoral artery or subclavian artery. There are also a wide variety of procedures which gain access to other body cavities in a minimally invasive fashion.
One problem which must be addressed during these procedures is how to seal or close the opening in the blood vessel or other body cavity once the treatment procedure has been completed. Some prior techniques include simply applying pressure to the opening until it seals itself sufficiently that the pressure may be released. However, this technique often requires that pressure must be consistently applied for an undesirable amount of time after the procedure. Similarly, this type of technique can require a patient's hospitalization to be extended until the treating physician is certain that the closure is complete.
Other techniques have involved suturing the wall of the vessel or body cavity itself. This has typically required the physician to peel back a rather large portion of the tissue surrounding the puncture in order to gain sufficient access to the blood vessel or body cavity that it may be sutured adequately. This can be an undesirably time consuming procedure, and it can result in significant discomfort to the patient.
Still other techniques have involved the insertion of embolic materials adjacent the puncture. Of course, this carries with it its own difficulties. For instances, it is desirable that the embolic material not be placed within a blood vessel or body cavity because this can result in an embolus forming within the blood vessel or body cavity. Similarly, however, it is desirable that the embolic material not be located to far proximal of the puncture because this can result in the blood vessel or body cavity bleeding into the interstitial space proximal of the opening in the blood vessel or body cavity, but distal to the embolic material.
Another technique used to close the opening in the blood vessel or other body cavity once the treatment procedure has been completed is to insert an expandable hemostatic member into the opening. For example, the member can be at least sponge-like material which expands to fill the opening thereby close the opening. However, it can be difficult to properly place the expandable member in the opening because in its expanded state, the member has a size which is greater than that provided by the opening.
An apparatus for closing a puncture site in a blood vessel wall includes an expandable hemostatic member comprising a biocompatible hydrophilic or water absorbing matrix configured to expand from a compressed or contracted state when exposed to body fluid and thereby seal the puncture site in the blood vessel wall. A control layer surrounds the hemostatic member and delays expansion of the hemostatic member from the compressed/contracted state after exposure to body fluid. The control layer can be of appropriate water soluble materials.
The expandable hemostatic member 12 is shown in a contracted state and is configured to expand upon exposure to body fluid. The present invention provides an improved hemostatic insert 10 for closing a puncture site such as those created through interventional angioplasty. The control layer 14 delays the expansion of the expandable hemostatic member 12 when exposed to body fluid This allows the hemostatic insert 10 to be placed into the puncture site and positioned as desired in a compressed state. This overcomes drawbacks associated with prior art hemostatic collagen/gelatin sponges in which the sponge swells before reaching the puncture site. When in the contracted state, the member 12 has a volume that is less than when in the expanded state. The change in volume can be through any appropriate technique. The present invention makes delivery of the hemostatic insert 10 easier and reduces the likelihood that the member is damaged or otherwise compromised during the insertion process. Because the member 12 has a smaller volume in the contracted state and can be easily introduced through a small opening. Further, the control layer 14 can provide a smooth and/or lubricious surface which promotes insertion into the puncture site.
In general, the expandable hemostatic member 12 is of a biocompatible material which expands when exposed to liquid. Similarly, the control layer should be of a biocompatible material which delays penetration of the liquid into the member 12. The control layer of 12 may be softening or soluble upon contact of body fluid. The layer 12 may further become lubricious when exposed to body fluid. In one example, member 12 comprises a collagen/gelatin sponge. The member 12 can be a gel formed from denatured collagen, foam, solid or a sponge matrix. Natural or synthetic polymer gels may also be employed. During the expansion, the member 12 provides a outwardly directed force such that it seals against the walls of the opening and is secured therein. During typical surgical applications, the member 12 should expand sufficiently in less than a few minutes after exposure to water. However, in some embodiments, it may be desirable for the delay to be significantly longer, for example, days or even weeks.
In one example, the member 12 comprises a sponge material which is coated with alginate and then cross linked with a low concentration of calcium. This provides a multi-valient cation cross linked alginate which is not water soluble and which has relatively low water permeability. However, the cross linking of the alginate by a multi-valient such as calcium is reversible when it is exposed to sequestrants. When the cross linked alginate is introduced into a patient, the calcium is removed by body fluid, and the alginate dissolves. After the alginate protective layer has been partially or completely removed, the body fluid enters the expandable hemostatic member 12. This causes member 12 to swell and thereby seal the puncture hole. Further, the characteristics of the dissolving of the algen, and the expansion of the expandable hemostatic member 12, can be controlled by controlling the alginate composition, the cross linking density, the coating thickness of the control layer 14 and other parameters.
In one specific example, a 1% alginate (molecular weight 2 million) aqueous solution is applied to a collagen sponge by spraying. The solution is allowed to dry. In another example, between 0.2% and a 3% alginate aqueous solution is used. Next, 20% calcium chloride aqueous solution is sprayed onto the dried alginate. In another example, between a 5% and a 30% calcium chloride aqueous solution is used. The calcium chloride solution is then allowed to dry. The thickness of the alginate/calcium protective layer is preferably between about 1 and about 5 microns. The resultant control layer operates in accordance with the present invention and allows controlled swelling of the collagen sponge.
In another specific example, a collagen sponge is coated, with a cellulous composition such as high molecular weight hydroxyl propyl cellulose (HPC). The HPC forms a thin shell on the exterior of the sponge. When the HPC is exposed to liquid, the HPC is slowly hydrated and dissolves. HPC swells as the liquid moves through the coating until the liquid reaches the expandable member 12. This causes expandable member 12 to expand. The expansion causes further disruption of the HPC coating allowing more rapid expansion of member 12. Any appropriate coating system can be used. Other polymer systems that act in this manner include hydroxypropylmethyl cellulose, high molecular weight polyethylene oxide, copolymers of methylvinyl ether, maleic anhydride and other plastic water soluble type materials. A cross-linked hydrogel system allows water to permeate the coating and swelling of the expandable hemostatic member 12 will occur if the coating is friable. In some embodiments, a rapidly hydrolizing polymer can be used. In some embodiments, a longer delay may be desirable, for example, to allow healing of adjacent tissue prior to full expansion of the member 12. The time delay due to the HPC layer can be controlled by the molecular weight of the HPC, the thickness of the HPC and by including additives in the HPC, for example. In one specific embodiment, a 5% (preferably between 1% and 8%) HPC aqueous solution (molecular weight 1.5 million) is spray coated onto a collagen sponge and allowed to dry.
Although spray coatings have been described, other coating techniques can be used including dipped coatings, suspension coatings, fluidized coatings, plasma coatings, etc. Further other types of ultra hyrophilic polymers can be used as a control layer 14 such as high molecular weight polyacrylic acid, acrylic acid/acrylamide copolymer, polyhydroxylethyl methacrylate (polyHEMA) (molecular weight greater than 1 million, etc. In embodiments in which the control layer 12 dissolves, the dissolved material should also be biocompatible.
As discussed above, the hemostatic insert 10 is used to seal puncture sites in a patient.
The particular insertion method and apparatus shown in
Although the present invention has been described with reference to preferred embodiments, workers skilled in the art will recognize that changes may be made in form and detail without departing from the spirit and scope of the invention. Although the protective layer 14 is described as being responsive to exposure to liquid, other techniques can also be used to trigger expansion of expandable hemostatic member 12. These techniques include exposure to heat, radio signals, radiation, ultrasonic signals, chemicals, etc. In another aspect, the control layer provides a desired shape to the hemostatic insert. For example, the control layer can be used to provide a pointed shape which allows for easier insertion of the hemostatic layer into the puncture site. The control layer can be from water soluble materials used in the pharmaceutical industry that includes materials such as maleic anhydrides and water soluble acrylics. Water soluble coatings (acrylic, cellulosic) can be obtained from Eastman, BASF, Rhom, Poulenc, and other sources.
The present application is a Continuation-In-Part of and claims priority of U.S. patent application Ser. No. 10/325,710, filed Dec. 20, 2002, now abandoned the content of which is hereby incorporated by reference in its entirety.
Number | Name | Date | Kind |
---|---|---|---|
3438374 | Falb et al. | Apr 1969 | A |
3847652 | Fletcher et al. | Nov 1974 | A |
4002173 | Manning et al. | Jan 1977 | A |
4068655 | LeRoy | Jan 1978 | A |
4140537 | Luck et al. | Feb 1979 | A |
4286341 | Greer et al. | Sep 1981 | A |
4292972 | Pawelchak et al. | Oct 1981 | A |
4365621 | Brundin | Dec 1982 | A |
4372314 | Wall | Feb 1983 | A |
4390519 | Sawyer | Jun 1983 | A |
4404970 | Sawyer | Sep 1983 | A |
4405324 | Cruz, Jr. | Sep 1983 | A |
4424208 | Wallace et al. | Jan 1984 | A |
4509504 | Brundin | Apr 1985 | A |
4515637 | Cioca | May 1985 | A |
4543410 | Cruz, Jr. | Sep 1985 | A |
4582640 | Smestad et al. | Apr 1986 | A |
RE32208 | Mattei et al. | Jul 1986 | E |
4597960 | Cohen | Jul 1986 | A |
4703108 | Silver et al. | Oct 1987 | A |
4744364 | Kensey | May 1988 | A |
4749689 | Miyata et al. | Jun 1988 | A |
4838280 | Haaga | Jun 1989 | A |
4852568 | Kensey | Aug 1989 | A |
4890612 | Kensey | Jan 1990 | A |
4979947 | Berman | Dec 1990 | A |
5021059 | Kensey et al. | Jun 1991 | A |
5061274 | Kensey | Oct 1991 | A |
5100429 | Sinofsky et al. | Mar 1992 | A |
5108421 | Fowler | Apr 1992 | A |
5192300 | Fowler | Mar 1993 | A |
5192302 | Kensey et al. | Mar 1993 | A |
5254105 | Haaga | Oct 1993 | A |
5290310 | Makower et al. | Mar 1994 | A |
5292309 | Van Tassel et al. | Mar 1994 | A |
5292332 | Lee | Mar 1994 | A |
5310407 | Casale | May 1994 | A |
5320639 | Rudnick | Jun 1994 | A |
5324306 | Makower et al. | Jun 1994 | A |
5330445 | Haaga | Jul 1994 | A |
5334216 | Vidal et al. | Aug 1994 | A |
5376376 | Li | Dec 1994 | A |
5383891 | Walker | Jan 1995 | A |
5383897 | Wholey | Jan 1995 | A |
RE34866 | Kensey et al. | Feb 1995 | E |
5391183 | Janzen et al. | Feb 1995 | A |
5431639 | Shaw | Jul 1995 | A |
5449375 | Vidal et al. | Sep 1995 | A |
5456693 | Conston et al. | Oct 1995 | A |
5460621 | Gertzman et al. | Oct 1995 | A |
5486195 | Myers et al. | Jan 1996 | A |
5522840 | Krajicek | Jun 1996 | A |
5540715 | Katsaros et al. | Jul 1996 | A |
5569297 | Makower et al. | Oct 1996 | A |
5603698 | Roberts et al. | Feb 1997 | A |
5624669 | Leung et al. | Apr 1997 | A |
5643318 | Tsukernik et al. | Jul 1997 | A |
5643596 | Pruss et al. | Jul 1997 | A |
5645849 | Pruss et al. | Jul 1997 | A |
5702413 | Lafontaine | Dec 1997 | A |
5716375 | Fowler | Feb 1998 | A |
5718916 | Scherr | Feb 1998 | A |
5728132 | Van Tassel et al. | Mar 1998 | A |
5782860 | Epstein et al. | Jul 1998 | A |
5782861 | Cragg et al. | Jul 1998 | A |
5823198 | Jones et al. | Oct 1998 | A |
5868762 | Cragg et al. | Feb 1999 | A |
5895412 | Tucker | Apr 1999 | A |
5906631 | Imran | May 1999 | A |
5964782 | Lafontaine et al. | Oct 1999 | A |
RE36370 | Li | Nov 1999 | E |
5980550 | Eder et al. | Nov 1999 | A |
5980559 | Bonutti | Nov 1999 | A |
5984950 | Cragg et al. | Nov 1999 | A |
6071300 | Brenneman et al. | Jun 2000 | A |
6071301 | Cragg et al. | Jun 2000 | A |
6086607 | Cragg et al. | Jul 2000 | A |
6162192 | Cragg et al. | Dec 2000 | A |
6162240 | Cates et al. | Dec 2000 | A |
6183496 | Urbanski | Feb 2001 | B1 |
6183497 | Sing et al. | Feb 2001 | B1 |
6183498 | Devore et al. | Feb 2001 | B1 |
6200328 | Cragg et al. | Mar 2001 | B1 |
6238687 | Mao et al. | May 2001 | B1 |
6267761 | Ryan | Jul 2001 | B1 |
6270464 | Fulton, III et al. | Aug 2001 | B1 |
6280474 | Cassidy et al. | Aug 2001 | B1 |
6299619 | Greene, Jr. et al. | Oct 2001 | B1 |
6315753 | Cragg et al. | Nov 2001 | B1 |
6350274 | Li | Feb 2002 | B1 |
6440151 | Cragg et al. | Aug 2002 | B1 |
6440153 | Cragg et al. | Aug 2002 | B2 |
6447534 | Cragg et al. | Sep 2002 | B2 |
6500152 | Illi | Dec 2002 | B1 |
6500190 | Greene, Jr. et al. | Dec 2002 | B2 |
6554851 | Palasis et al. | Apr 2003 | B1 |
6605294 | Sawhney | Aug 2003 | B2 |
6699261 | Cates et al. | Mar 2004 | B1 |
20020010150 | Cortese et al. | Jan 2002 | A1 |
20020025921 | Petito et al. | Feb 2002 | A1 |
20020151918 | Lafontaine et al. | Oct 2002 | A1 |
20030004568 | Ken et al. | Jan 2003 | A1 |
20030013989 | Obermiller et al. | Jan 2003 | A1 |
20060034930 | Khosravi et al. | Feb 2006 | A1 |
Number | Date | Country |
---|---|---|
0 044 624 | Jan 1982 | EP |
0 145 970 | Nov 1983 | EP |
0 044 624 | Oct 1984 | EP |
0467516 | Jan 1992 | EP |
A0645150 | Mar 1995 | EP |
0 891 193 | Apr 1997 | EP |
0 726 749 | Jan 2000 | EP |
1 269 951 | Jan 2003 | EP |
55116736 | Sep 1980 | JP |
62004232 | Jan 1987 | JP |
63070507 | Apr 1988 | JP |
02182259 | Jul 1990 | JP |
05163157 | Jun 1993 | JP |
09294765 | Nov 1997 | JP |
2002143210 | May 2002 | JP |
2122867 | Dec 1998 | RU |
2135105 | Aug 1999 | RU |
2165741 | Apr 2001 | RU |
2178681 | Jan 2002 | RU |
2179859 | Feb 2002 | RU |
2180539 | Mar 2002 | RU |
2185858 | Jul 2002 | RU |
WO 9512371 | May 1995 | WO |
WO 9640033 | Dec 1996 | WO |
WO 9737694 | Oct 1997 | WO |
WO 0029484 | May 2000 | WO |
WO 0182937 | Nov 2001 | WO |
WO 0197826 | Dec 2001 | WO |
WO 0209591 | Feb 2002 | WO |
WO 0209591 | Feb 2002 | WO |
WO 02054998 | Jul 2002 | WO |
WO 02072128 | Sep 2002 | WO |
WO 02096302 | Dec 2002 | WO |
WO 03002168 | Jan 2003 | WO |
Entry |
---|
“Notification of Transmittal of the International Search Report or the Declaration”, PCT/US2004/018885. |
Number | Date | Country | |
---|---|---|---|
20040122350 A1 | Jun 2004 | US |
Number | Date | Country | |
---|---|---|---|
Parent | 10325710 | Dec 2002 | US |
Child | 10460747 | US |